Trial Profile

A post-marketing survey evaluating the safety and efficacy of a fixed-dose single-pill combination of cilnidipine and valsartan in patients with hypertension

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cilnidipine/valsartan (Primary)
Indications Hypertension
Focus Adverse reactions; Therapeutic Use
Acronyms HOPE-Combi survey
Sponsors EA Pharma

Most Recent Events

17 Jan 2021 Results (n=616) of subanalysis of HOPE Combi survey assessing efficacy of the SPC of Cil/Val on the day by day variability of morning home systolic BP (MHSBP) in patients with treated hypertension in real world settings, published in the Journal of Clinical Hypertension (Greenwich)
01 Mar 2020 Results published in the Journal of Clinical Hypertension (Greenwich)
31 Jul 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com